Evidence map›Paper›PMID 40861898›Full record

ArticleMolecular therapy. Nucleic acids2025

Development of conditional-siRNA programmable riboswitch for targeting adverse cardiac remodeling.

Priyanka Gokulnath, Ane M Salvador, Caleb Graham, Si-Ping Han, Guoping Li, Ramaswamy Kannappan, Christopher Azzam, Michail Spanos, Lisa Scherer, Palaniappan Sethu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Priyanka GokulnathCardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Ane M SalvadorCardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Caleb GrahamUniversity of Alabama at Birmingham, Birmingham, AL 35294, USA.
Si-Ping HanDepartment of Molecular and Cellular Biology, City of Hope, Duarte, CA 91010, USA.
Guoping LiCardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Ramaswamy KannappanUniversity of Alabama at Birmingham, Birmingham, AL 35294, USA.
Christopher AzzamCardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Michail SpanosCardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Lisa SchererDepartment of Molecular and Cellular Biology, City of Hope, Duarte, CA 91010, USA.
Palaniappan SethuUniversity of Alabama at Birmingham, Birmingham, AL 35294, USA.
John RossiDepartment of Molecular and Cellular Biology, City of Hope, Duarte, CA 91010, USA.
William A GoddardMaterials and Process Simulation Center, California Institute of Technology, Pasadena, CA 91125, USA.
Saumya DasCardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

Funding

Functional role and therapeutic targeting of exosomes and extracellular RNA biomarkers in heart failureR35HL150807 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Saumya Das · 2020 to 2026
$6.7M
NHLBI NIH HHS R35 HL150807
6 · The paper itself

Abstract

Heart failure (HF) remains a significant healthcare burden, with an unmet need for novel therapies to target the preceding pathological hypertrophy in HF patients. Here we report the development of novel conditional-siRNA (

Indexed as

calcineurincardiac hypertrophyheart failureheart-on-chip modelMT: Oligonucleotides: Therapies and ApplicationsriboswitchRNA therapeuticssiRNAtissue-specific therapy

Identifiers

PMID40861898
PMCPMC12375242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.